Companies/US/RPRX

ROYALTY PHARMA PLC

Income flow

Annual
RPRX 10-K Income StatementPeriod 2025-12-31Source 10-K
Financial Royalty Assets$2BRoyalty Income Other$117MRevenue$2B+5% Y/YGross profit$2B+21% Y/YCost of revenue$819MOperating profit$2B+21% Y/YPre-tax profit$1BOther expenses$235MNet profit$771M-10% Y/YTax$553M

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 10-K · USD
By activity
By activity$2.4B
  • Financial Royalty Assets$2.3B95.1%
  • Royalty Income Other$117M4.9%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).1.65%5y avgAverage dividend yield over the past five years — a smoother view than the latest print.2.17%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0.91PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.48.4%Shares outTotal shares currently outstanding (issued and not retired).445.3MFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).417.6M
Dividend calendar
Ex-dividend
2026-08-14
Pay date
2026-09-10
Last cash
0.235 · 2026-08-14

Valuation

Trailing PE 21.4 (2025-12-31)PE trend

Fiscal PE5

PeriodEPSClosePE
2025-12-311.7838.1221.4
2024-12-311.9124.5512.8
2023-12-312.5326.2110.4
2022-12-310.135.95359.5
2021-12-311.4935.623.9

PE = stored close ÷ as-filed diluted EPS (annual 10-K / 20-F). Not a vendor PE series.